目的 研究參松養(yǎng)心膠囊聯(lián)合鹽酸伊伐布雷定片治療慢性心力衰竭的臨床療效。方法 選取2017年6月-2019年12月在光山縣人民醫(yī)院治療的84例慢性心力衰竭患者為研究對象，所有患者隨機(jī)分為對照組和治療組，每組各42例。對照組患者口服鹽酸伊伐布雷定片，1片/次，2次/d。治療組在對照組治療的基礎(chǔ)上口服參松養(yǎng)心膠囊，3粒/次，3次/d。兩組患者持續(xù)治療2周。觀察兩組患者臨床療效，比較兩組的生活質(zhì)量綜合評定問卷（GQOLI-74）評分、明尼蘇達(dá)心功能不全生活量表（MHLFQ）評分、6 min步行試驗（6MWT）、心功能指標(biāo)、血清學(xué)指標(biāo)水平、血清炎性因子水平。結(jié)果 治療后，治療組總有效率為92.86%，顯著高于對照組的84.33%（P<0.05）。治療后，兩組患者左心室收縮末期容積（LVESV）、左心室舒張末期內(nèi)徑（LVEDD）顯著降低，左心室射血分?jǐn)?shù)（LVEF）顯著升高（P<0.05），且治療組左心功能指標(biāo)改善較多（P<0.05）。治療后，兩組患者M(jìn)HLFQ評分顯著降低，6MWT和GQOLI-74評分明顯升高（P<0.05）；且治療組改善較多（P<0.05）。治療后，兩組血清N末端B型鈉尿肽原（NT-proBNP）和肌鈣蛋白T（cTnT）水平顯著降低（P<0.05）；并且治療組血清NT-proBNP和cTnT水平降低較多（P<0.05）。治療后，兩組患血清白細(xì)胞介素（IL）-6、腫瘤壞死因子α（TNF-α）、超敏C反應(yīng)蛋白（hs-CRP）水平顯著降低（P<0.05）；并且治療組血清炎性因子水平降低較多（P<0.05）。結(jié)論 參松養(yǎng)心膠囊聯(lián)合鹽酸伊伐布雷定片治療慢性心力衰竭具有較好的療效，能夠改善患者心功能和生活質(zhì)量，降低血清學(xué)指標(biāo)和血清炎性因子水平，安全性較高，值得在臨床上推廣應(yīng)用。

Objective To study the efficacy of Shensong Yangxin Capsules combined with Ivabradine Hydrochloride Tablets in treatment of chronic heart failure. Methods Patients (84 cases) with chronic heart failure in Guangshan People's Hospital from June 2017 to December 2019 were randomly divided into control and treatment groups, and each group had 42 cases. Patients in the control group were po administered with Ivabradine Hydrochloride Tablets, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Shensong Yangxin Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and GQOLI-74 score, MHLFQ score, 6MWT, cardiac function index, the serum level of serological index and inflammatory factors in two groups were compared. Results After treatment, the total effective rate of the treatment group was 92.86%, which was significantly higher than that of the control group (84.33%) (P<0.05). After treatment, the LVESV and LVEDD of the two groups were significantly decreased, but the LVEF of the two groups were significantly increased (P<0.05). And the indexes of left heart function in the treatment group were better than those in the control group (P<0.05). After treatment, the MHLFQ scores of the two groups were significantly decreased, but 6MWT and GQOLI-74 scores of the two groups were significantly increased (P<0.05). And the indexes in the treatment group were better than those in the control group (P<0.05). After treatment, the levels of NT-proBNP and cTnT in two groups were significantly decreased (P<0.05). And the levels of NT-proBNP and cTnT in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the serum levels of IL-6, TNF- and hs-CRP in two groups were significantly decreased (P<0.05). And the serum inflammatory factors in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Shensong Yangxin Capsules combined with Ivabradine Hydrochloride Tablets has clinical curative effect in treatment of chronic heart failure, can improve the cardiac function and quality of life of patients, reduce serological indexes and serum inflammatory factors, with good safety, which is worthy of clinical application.

R972